©The Author(s) 2017.
World J Hepatol. May 28, 2017; 9(15): 697-703
Published online May 28, 2017. doi: 10.4254/wjh.v9.i15.697
Published online May 28, 2017. doi: 10.4254/wjh.v9.i15.697
Table 3 Immunosuppressive drugs and metabolic side effects affecting post-liver transplantation cardiovascular risk[33]
| Drug | Group | Side effects |
| Corticosteroids | Dyslipidemia ++ | |
| AHT +++ | ||
| DM +++ | ||
| Renal impairment - | ||
| Mycophenolate mofetil | De novo purine synthesis inhibitor | Dyslipidemia - |
| AHT - | ||
| DM - | ||
| Renal impairment - | ||
| Cyclosporine | Calcineurin inhibitors | Dyslipidemia ++ |
| Tacrolimus | AHT +++ | |
| DM ++ | ||
| Renal impairment ++ | ||
| Sirolimus | mTOR inhibitors | Dyslipidemia +++ |
| Everolimus | AHT - | |
| DM - | ||
| Renal impairment - |
- Citation: Sanchez-Torrijos Y, Ampuero J, Romero-Gómez M. Cardiovascular assessment in liver transplant for non-alcoholic steatohepatitis patients: What we do, what we should do. World J Hepatol 2017; 9(15): 697-703
- URL: https://www.wjgnet.com/1948-5182/full/v9/i15/697.htm
- DOI: https://dx.doi.org/10.4254/wjh.v9.i15.697